Old drug, new hope: could papaverine soothe chemo nerve damage?
NCT ID NCT07572461
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether papaverine, a drug that relaxes blood vessels, can relieve nerve pain and numbness caused by taxane chemotherapy. About 43 adults whose symptoms haven't improved with standard treatments will receive daily infusions of papaverine for up to three weeks. The goal is to see if it reduces sensory symptoms and improves quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
papaverine hydrochloride injection
What this could lead to
If it works, this could offer a new option for people with nerve pain from chemotherapy that hasn't improved with standard treatments.
What could go wrong
This is a small, early-phase study with no control group, so results may not be conclusive. It's also not yet recruiting, so outcomes are uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••